QCM
ELTX icon

Quantinno Capital Management’s Elicio Therapeutics ELTX Stock Holding History

Quantinno Capital Management’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,000
Closed -$154K – 2952
2025
Q2 		$154K Hold
20,000
– – ﹤0.01% 2430
2025
Q1 		$123K Buy
+20,000
New +$155K ﹤0.01% 1982

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Quantinno Capital Management's ELTX Position: Q3 2025 in Review

Quantinno Capital Management sold out of Elicio Therapeutics (ELTX) in Q3 2025, closing a stake of 20,000 shares — an estimated $154K sold.

Quantinno Capital Management first reported a position in ELTX in Q1 2025 and held it in 2 quarters. The position peaked at $154K in Q2 2025. 28 funds tracked by Wall St. Rank hold ELTX as of Q3 2025.

  • Quantinno Capital Management reported no remaining Elicio Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Quantinno Capital Management sold 20,000 Elicio Therapeutics shares in Q3 2025, an estimated $154K.
  • Quantinno Capital Management first reported a position in Elicio Therapeutics in Q1 2025 and held it in 2 quarters.
  • Quantinno Capital Management's Elicio Therapeutics position peaked at $154K in Q2 2025.
  • 28 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2025.

Based on Quantinno Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.